Clinical Trials
70 trialsBHARAT-1
Aurigene Discovery Technologies Limited
Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Changchun GeneScience Pharmaceutical Co., Ltd.
LAUREL
Inmune Bio, Inc.
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
Servier
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
Shattuck Labs, Inc.
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
NextCure, Inc.
STIMULUS-MDS2
Novartis
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Sanofi
A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies
Kahr Medical
An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
Incyte Corporation
LIMBER
Incyte Corporation
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
ACHIEVE
TC Biopharm
A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Bristol-Myers Squibb
Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes
Celgene
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS
Vor Biopharma
AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia
Amgen
Connect® Myeloid Disease Registry
Celgene
A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
Celgene
A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS
Aptose Biosciences Inc.
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies
Ensoma
A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS
Cyclacel Pharmaceuticals, Inc.
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
Astex Pharmaceuticals, Inc.
A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Astex Pharmaceuticals, Inc.
A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies
Amgen
A Study of ONO-7475 in Patients With Acute Leukemias
Ono Pharmaceutical Co., Ltd.
IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome
IGF Oncology, LLC
An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia
Kyowa Kirin Co., Ltd.
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Pfizer
Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Kyowa Kirin Co., Ltd.
Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome
AbbVie
Encore-MDS
Hemavant Sciences GmbH
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
Prelude Therapeutics
A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS
Sumitomo Pharma America, Inc.
Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma
Bellicum Pharmaceuticals
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
Bellicum Pharmaceuticals
THRIVE
Bellicum Pharmaceuticals
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
Bellicum Pharmaceuticals
Thrombosomes® in Bleeding Thrombocytopenic Patients Study
Cellphire Therapeutics, Inc.
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
Amgen
CATHY
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
GlaxoSmithKline
Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
GT Biopharma, Inc.
HATCY
Kiadis Pharma
A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies
Bayer
Study of INCB053914 in Subjects With Advanced Malignancies
Incyte Corporation
Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Daiichi Sankyo
Phase I Study of Milatuzumab for Graft Versus Host Disease
Gilead Sciences
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor
Kiadis Pharma